270 related articles for article (PubMed ID: 33368437)
1. Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yes-Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans.
Wang H; Song X; Liao H; Wang P; Zhang Y; Che L; Zhang J; Zhou Y; Cigliano A; Ament C; Superville D; Ribback S; Reeves M; Pes GM; Liang B; Wu H; Evert M; Calvisi DF; Zeng Y; Chen X
Hepatology; 2021 Jul; 74(1):248-263. PubMed ID: 33368437
[TBL] [Abstract][Full Text] [Related]
2. SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelial-Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model.
Xu M; Wang J; Xu Z; Li R; Wang P; Shang R; Cigliano A; Ribback S; Solinas A; Pes GM; Evert K; Wang H; Song X; Zhang S; Che L; Pascale RM; Calvisi DF; Liu Q; Chen X
Cancer Res; 2019 Nov; 79(21):5563-5574. PubMed ID: 31383647
[TBL] [Abstract][Full Text] [Related]
3. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Xia H; Ooi LL; Hui KM
Hepatology; 2013 Aug; 58(2):629-41. PubMed ID: 23471579
[TBL] [Abstract][Full Text] [Related]
5. Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver.
Li X; Tao J; Cigliano A; Sini M; Calderaro J; Azoulay D; Wang C; Liu Y; Jiang L; Evert K; Demartis MI; Ribback S; Utpatel K; Dombrowski F; Evert M; Calvisi DF; Chen X
Oncotarget; 2015 Apr; 6(12):10102-15. PubMed ID: 25826091
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of MAFG Dysregulation in Cholestatic Liver Injury and Development of Liver Cancer.
Liu T; Yang H; Fan W; Tu J; Li TWH; Wang J; Shen H; Yang J; Xiong T; Steggerda J; Liu Z; Noureddin M; Maldonado SS; Annamalai A; Seki E; Mato JM; Lu SC
Gastroenterology; 2018 Aug; 155(2):557-571.e14. PubMed ID: 29733835
[TBL] [Abstract][Full Text] [Related]
8. YAP is a critical oncogene in human cholangiocarcinoma.
Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
[TBL] [Abstract][Full Text] [Related]
9. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
[TBL] [Abstract][Full Text] [Related]
10. Programmed cell death 10 promotes metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma via PP2Ac-mediated YAP activation.
Sun B; Zhong FJ; Xu C; Li YM; Zhao YR; Cao MM; Yang LY
Cell Death Dis; 2021 Sep; 12(9):849. PubMed ID: 34521817
[TBL] [Abstract][Full Text] [Related]
11. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
[TBL] [Abstract][Full Text] [Related]
12. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
13. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.
Tschaharganeh DF; Chen X; Latzko P; Malz M; Gaida MM; Felix K; Ladu S; Singer S; Pinna F; Gretz N; Sticht C; Tomasi ML; Delogu S; Evert M; Fan B; Ribback S; Jiang L; Brozzetti S; Bergmann F; Dombrowski F; Schirmacher P; Calvisi DF; Breuhahn K
Gastroenterology; 2013 Jun; 144(7):1530-1542.e12. PubMed ID: 23419361
[TBL] [Abstract][Full Text] [Related]
14. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
15. Smad7 regulates compensatory hepatocyte proliferation in damaged mouse liver and positively relates to better clinical outcome in human hepatocellular carcinoma.
Feng T; Dzieran J; Gu X; Marhenke S; Vogel A; Machida K; Weiss TS; Ruemmele P; Kollmar O; Hoffmann P; Grässer F; Allgayer H; Fabian J; Weng HL; Teufel A; Maass T; Meyer C; Lehmann U; Zhu C; Mertens PR; Gao CF; Dooley S; Meindl-Beinker NM
Clin Sci (Lond); 2015 Jun; 128(11):761-74. PubMed ID: 25602745
[TBL] [Abstract][Full Text] [Related]
16. Loss of KLF4 and consequential downregulation of Smad7 exacerbate oncogenic TGF-β signaling in and promote progression of hepatocellular carcinoma.
Sun H; Peng Z; Tang H; Xie D; Jia Z; Zhong L; Zhao S; Ma Z; Gao Y; Zeng L; Luo R; Xie K
Oncogene; 2017 May; 36(21):2957-2968. PubMed ID: 28192402
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.
Oishi N; Kumar MR; Roessler S; Ji J; Forgues M; Budhu A; Zhao X; Andersen JB; Ye QH; Jia HL; Qin LX; Yamashita T; Woo HG; Kim YJ; Kaneko S; Tang ZY; Thorgeirsson SS; Wang XW
Hepatology; 2012 Nov; 56(5):1792-803. PubMed ID: 22707408
[TBL] [Abstract][Full Text] [Related]
18. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
19. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
[TBL] [Abstract][Full Text] [Related]
20. LncRNA CSMD1-1 promotes the progression of Hepatocellular Carcinoma by activating MYC signaling.
Liu J; Xu R; Mai SJ; Ma YS; Zhang MY; Cao PS; Weng NQ; Wang RQ; Cao D; Wei W; Guo RP; Zhang YJ; Xu L; Chen MS; Zhang HZ; Huang L; Fu D; Wang HY
Theranostics; 2020; 10(17):7527-7544. PubMed ID: 32685003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
